MPM BioImpact’s Adlai Nortye Group ANL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$31.3M Buy
1,956,618
+20,327
+1% +$273K 2.32% 19
2026
Q2
$22.3M Buy
+1,936,291
New +$23.6M 1.36% 27

Other funds holding ANL

MPM BioImpact's ANL Position: Q3 2026 in Review

MPM BioImpact increased its Adlai Nortye Group (ANL) stake by 1% in Q3 2026, buying an estimated $273K and bringing the position to 1,956,618 shares worth $31.3M. The position accounts for 2.32% of the portfolio, ranked #19.

MPM BioImpact first reported a position in ANL in Q2 2026 and has held it in 2 quarters since. 52 funds tracked by Wall St. Rank hold ANL as of Q3 2026.

  • MPM BioImpact held 1,956,618 shares of Adlai Nortye Group worth $31.3M as of Q3 2026.
  • MPM BioImpact bought 20,327 Adlai Nortye Group shares in Q3 2026, an estimated $273K.
  • Adlai Nortye Group made up 2.32% of MPM BioImpact's portfolio in Q3 2026, its #19 holding.
  • MPM BioImpact first reported a position in Adlai Nortye Group in Q2 2026 and has held it in 2 quarters since.
  • 52 funds tracked by Wall St. Rank held Adlai Nortye Group as of Q3 2026.

Based on MPM BioImpact's 13F filing for Q3 2026, filed 16 Nov 2026.